Site Logo
  1. Home
  2. Past Issues
  3. Summary Vol.85 Issue 2 / 2022
  4. Article
Letters to the Editor
Views

Arq. Bras. Oftalmol. 2022; 85 (2): 10.5935/0004-2749.20220095

Total: 2092

The renin-angiontensin system and the development of new antiglaucoma medications

Aline Ruilowa de Pinho Coelho1; Rodrigo da Silva Santos2; Angela Adamski da Silva Reis1,2

DOI: 10.5935/0004-2749.20220095

1. Postgraduate Program in Health Science, Faculty of Medicine, Universidade Federal de Goiás, Goiânia, GO, Brazil
2. Laboratory of Molecular Pathology, Department of Biochemistry and Molecular Biology, Institute of Biological Sciences, Universidade Federal de Goiás, Goiânia, GO, Brazil

Corresponding author

Angela Adamski da Silva Reis and Rodrigo da Silva Santos
E-mails: [email protected]; [email protected]

Funding: This study received no specific financial support

Disclosure of potential conflicts of interest: None of the authors have any potential conflicts of interest to disclose


Read in Portuguese Print PDF English
Open Access
Share

How to cite this article:

Coelho ARP, Santos RS, Reis1 AAS, 2 . O sistema renina-angiotensina e o desenvolvimento de novos medicamentos antiglaucoma. Arq. Bras. Oftalmol. 2022;85(2):. 10.5935/0004-2749.20220095
Export citation